A large prospective study in breast cancer identified a switch in receptor status for ER in 10.2% of patients, for PR in 24.8%, and for HER2 in 2.9%; the switch in receptor status led to a change in the subsequent treatment plan for 17.5% of patients [21]. The gene discussed is ERBB2; the disease is breast carcinoma.